Business Context and Reporting Period
Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996
Business Overview: Daxor operates clinical laboratories (including blood banking and pathology services) and invests in marketable securities. The company is also developing the Blood Volume Analyzer (BVA-100) instrument.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 1996 | 9 Months Ended Sep 30, 1995 | 3 Months Ended Sep 30, 1996 | 3 Months Ended Sep 30, 1995 |
|---|---|---|---|---|
| Total Revenues | $2,223,536 | $3,325,114 | $764,680 | $991,284 |
| Operating Revenues | $632,416 | $1,188,521 | $200,851 | $254,928 |
| Dividend Income | $1,581,758 | $1,633,637 | $538,866 | $528,262 |
| Net Income (Loss) | $(112,731) | $1,090,457 | $14,239 | $222,352 |
| Net Income Per Share | $(0.02) | $0.22 | $0.01 | $0.05 |
| Cash Flow from Operations | $65,540 | $961,531 | N/A | N/A |
| Total Assets | $35,030,705 | $37,744,621 | N/A | N/A |
| Total Liabilities | $4,867,644 | $5,691,790 | N/A | N/A |
| Shareholders' Equity | $30,163,061 | $32,052,831 | N/A | N/A |
Liquidity and Debt:
- Cash: $89,805 (as of Sep 30, 1996).
- Marketable Securities: $33,230,471 (Fair Value).
- Loans Payable: $1,436,414 (Includes $200,000 bank loan and $1,227,216 margin debt).
- Unrealized Gains: $5,576,365 (Net of tax) included in equity.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 33% year-over-year for the nine-month period, driven primarily by a 47% drop in operating revenues ($632k vs $1.19M).
- Profitability Shift: The company reported a net loss of $112,731 for the nine months ended Sep 30, 1996, compared to a net income of $1.09M in the prior year. The loss was driven by a $196,723 loss on the sale of options and commodities and higher selling, general, and administrative expenses.
- Operating Expenses: SG&A expenses increased to $1.61M (9 months 1996) from $1.41M (9 months 1995), despite lower revenues.
- Investment Portfolio: Net unrealized gains on securities decreased from $10.86M (Dec 31, 1995) to $8.85M (Sep 30, 1996), reducing total equity.
Outlook, Risks, and Management Commentary
Operational Challenges: Operations were negatively impacted by the partial closure of New York State facilities from August 1995 through May 1996. The Scientific Medical Systems division (pathology services), which historically provided ~20% of operating revenue, has not fully reopened.
Future Growth Drivers:
- BVA-100: Management anticipates the Blood Volume Analyzer and associated kits will become a major revenue source upon approval. A contract with Oxford Instruments, Inc. was signed in July 1996 for production.
- Expansion: The company is evaluating the purchase of another private blood banking corporation and a clinical laboratory, and considering expanding its stake in US Cryobanks of Florida.
Legal Contingencies: The company is involved in multiple significant legal proceedings against the State of New York Department of Health regarding regulations on semen banking and defamation claims. Several appeals are pending, including requests for leave to appeal to the Court of Appeals. Management notes that court victories have allowed facilities to reopen.
Capital Needs: Management states that additional capital may be required to sustain marketing plans for the BVA-100 and to expand blood banking operations on a national scale.
Investor Verification Checklist
- Regulatory Status: Verify the final outcome of pending appeals with the New York Court of Appeals regarding the Department of Health regulations.
- BVA-100 Approval: Confirm the regulatory approval status and commercial launch timeline for the Blood Volume Analyzer.
- Facility Capacity: Assess the current operational capacity of the New York facilities and the Scientific Medical Systems division post-closure.
- Capital Requirements: Review the specific capital needs for the proposed acquisition of blood banking corporations and the construction of a kit manufacturing facility.
- Investment Volatility: Monitor the unrealized gains/losses on the significant portfolio of marketable securities, which heavily influences reported equity.